Evaluation of serum midkine as a biomarker in differentiated thyroid cancer
- 1 June 2015
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 130, 18-24
Abstract
No abstract availableKeywords
Funding Information
- National Key Clinical Specialty Project
- Tianjin Medical University General Hospital New Century Excellent Talent Program
- Young and Middle-aged Innovative Talent Training Program
- Talent Fostering Program
This publication has 36 references indexed in Scilit:
- Circulating midkine in malignant and non-malignant colorectal diseasesCytokine, 2013
- A Low Postoperative Nonstimulated Serum Thyroglobulin Level Does Not Exclude the Presence of Radioactive Iodine Avid Metastatic Foci in Intermediate-Risk Differentiated Thyroid Cancer PatientsThyroid®, 2013
- The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancerWorld Journal of Surgical Oncology, 2010
- Induction of Thyroid Gene Expression and Radioiodine Uptake in Thyroid Cancer Cells by Targeting Major Signaling PathwaysThe Journal of Clinical Endocrinology & Metabolism, 2010
- Midkine as a prognostic biomarker in oral squamous cell carcinomaBritish Journal of Cancer, 2008
- Clinical significance of midkine expression in pancreatic head carcinomaBritish Journal of Cancer, 2007
- Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategyClinical Endocrinology, 2007
- Presurgical Serum Thyroglobulin Has No Prognostic Value in Papillary Thyroid CancerThyroid®, 2005
- Purification of recombinant midkine and examination of its biological activities: Functional comparison of new heparin binding factorsBiochemical and Biophysical Research Communications, 1991
- cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesisBiochemical and Biophysical Research Communications, 1988